December 8, 2016 07:20 AM EST

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

John Carroll

Editor & Founder

A year-and-a-half after launching their Phase III study of their lead drug Actimmune for Friedreich’s Ataxia, Horizon Pharma has had to call it quits after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Hori­zon Phar­ma folds its cards on Friedre­ich’s Atax­ia af­ter Ac­tim­mune flunks PhI­II

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva